# A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

Source: https://onco.cc/trials/nct00883116/  
OnCo record `nct00883116` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ixabepilone, Doxorubicin and Paclitaxel / nab-paclitaxel in Endometrial cancer, run by R-Pharm, recorded as terminated on the registry.

## Summary

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer is a phase 3 interventional study registered as NCT00883116 by R-Pharm, with 551 participants recorded, started 2009-08 and due to reach its primary completion in 2012-06. Interventions recorded: Ixabepilone, Doxorubicin, Paclitaxel. Conditions recorded: Endometrial Cancer.

Linked to the drug Ixabepilone because the registry names it among its interventions and Endometrial cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00883116
- Phase: 3
- Setting: A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy
- Sponsor: R-Pharm
- Enrolled: 551

## Sources

- ClinicalTrials.gov NCT00883116: https://clinicaltrials.gov/study/NCT00883116

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Ixabepilone](https://onco.cc/drugs/ixabepilone/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [R-Pharm](https://onco.cc/companies/r-pharm/)

---
JSON: https://onco.cc/api/v1/entities/nct00883116.json